<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625490</url>
  </required_header>
  <id_info>
    <org_study_id>202107042-2</org_study_id>
    <secondary_id>R01HL142297</secondary_id>
    <nct_id>NCT05625490</nct_id>
  </id_info>
  <brief_title>Myocardial Perfusion Imaging Galmydar Rest/Stress</brief_title>
  <official_title>Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, phase 0/1 clinical imaging study designed to assess the role of&#xD;
      [68Ga]Galmydar PET/CT imaging in human subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the proposed study is to evaluate the potential of [68Ga]Galmydar&#xD;
      PET/CT MPI for the noninvasive detection of coronary artery disease. The study will evaluate&#xD;
      [68Ga]Galmydar PET/CT MPI in comparison to [13N]ammonia PET/CT MPI to semi-quantitatively&#xD;
      assess regional myocardial perfusion and quantitatively assess myocardial blood flow (MBF) in&#xD;
      patients with suspected or known coronary artery disease (CAD) undergoing clinical SPECT MPI.&#xD;
      In addition, perfusion and MBF findings with [68Ga]Galmydar will be compared to the results&#xD;
      of coronary morphology or stenosis severity in those patients undergoing invasive coronary&#xD;
      angiography (ICA) based on abnormal SPECT MPI. The performance of rest/stress [68Ga]Galmydar&#xD;
      PET/CT in comparison to [13N]ammonia PET/CT in normal subjects without cardiovascular disease&#xD;
      will be performed as a control. The primary objective of the proposed study is to evaluate&#xD;
      the potential of [68Ga]Galmydar PET/CT MPI for the noninvasive detection of coronary artery&#xD;
      disease. The study will evaluate [68Ga]Galmydar PET/CT MPI in comparison to [13N]ammonia&#xD;
      PET/CT MPI in the same subjects to semi quantitatively assess regional myocardial perfusion&#xD;
      and quantitatively assess myocardial blood flow (MBF) in patients with suspected or known&#xD;
      coronary artery disease (CAD) undergoing clinical SPECT MPI. In addition, perfusion and MBF&#xD;
      findings with [68Ga]Galmydar will be compared to the results of coronary morphology or&#xD;
      stenosis severity in those patients undergoing invasive coronary angiography (ICA) based on&#xD;
      abnormal SPECT MPI. The performance of rest/stress [68Ga]Galmydar PET/CT in comparison to&#xD;
      [13N]ammonia PET/CT in normal subjects without cardiovascular disease will be performed as a&#xD;
      control. Vital signs, serum chemistries, and serum blood counts will also be obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with known or suspected disease and normal controls (no known disease) will both undergo [68Ga]Galmydar PET/CT MPI and [13N]ammonia PET/CT MPI</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Semiquantitative assessment of 68Ga-Galmydar PET/CT uptake</measure>
    <time_frame>Comparison to regional uptake on 13N-ammonia PET/CT performed 3-30 days after the 68Ga-Galmydar PET/CT</time_frame>
    <description>Assessment of regional (17segment) myocardial uptake on 5-point scale (0 = normal; 4 = absent tracer uptake) per independent blind readout by 3 expert cardiac PET physicians.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of myocardial blood flow on 68Ga-Galmydar PET/CT</measure>
    <time_frame>Comparison to regional MBF on 13N-ammonia PET/CT performed 3-30 days after the 68Ga-Galmydar PET/CT</time_frame>
    <description>Assessment of regional (17segment) myocardial blood flow (MBF) at stress and rest perfusion on 68Ga-Galmydar PET/CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic or diastolic blood pressure.</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>A 20 mmHg change from baseline in either systolic or diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate.</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>A 20 BPM change in heart rate from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in respiratory rate.</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>A respiratory rate of &lt; 12 or &gt; 20 breaths/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant elevation in oral temperature</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Oral temperature of &gt;100 degrees F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with new AV Block</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>A change in EKG showing new AV Block (Type 1 or Type 2), Mobitz 2:1, or QTc â‰¥ 500ms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with new bradycardia</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>New heart rate &lt; 40 BPM on EKG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in serum chemistries: sodium, potassium, chloride, CO2</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Serum chemistries (sodium, potassium, chloride, CO2) measured in mmol/L. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in serum chemistries: glucose, calcium creatinine, BUN, total bilirubin</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Serum chemistries (glucose, calcium creatinine, BUN, total bilirubin), measured in mg/dL. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in serum chemistries: total protein, albumin.</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Serum chemistries (total protein, albumin), measured in g/dL. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in serum chemistries: alkaline phosphatase, ALT, AST</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Serum chemistries (alkaline phosphatase), measured in U/L. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in white blood cell count (WBC)</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>White blood cell count measured in WBC/mm3 blood. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in hemoglobin (Hgb)</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Hgb measured in g/dL. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in hematocrit (Hct)</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Hct measured in %. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in platelets</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>Platelets measured in platelets/mm3 blood. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in red blood cell count (RBC)</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>RBC measured in million/mm3. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant change in mean corpuscular volume (MCV)</measure>
    <time_frame>6 hours from 68Ga-Galmydar injection</time_frame>
    <description>MCV measured in Âµm3. Values outside of laboratory range in comparison to baseline or &gt;20% difference from baseline values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Rest/ Stress imaging day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two [68Ga]Galmydar intravenous administrations, 4 mCi during rest and 8 mCi during stress for the PET MPI performed on Imaging Day-1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rest/ stress imaging day 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Imaging Day-2, participants will receive two single administrations each of 10 mCi of 13N-Ammonia during the rest and stress PET MPI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 Galmydar</intervention_name>
    <description>Two intravenous injection of the PET radiotracer 68Ga-Galmydar.</description>
    <arm_group_label>Rest/ Stress imaging day 1</arm_group_label>
    <other_name>IND 157468</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13N-ammonia</intervention_name>
    <description>Two intravenous Injection of PET radiotracer 13N-Ammonia.</description>
    <arm_group_label>rest/ stress imaging day 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female, 18-99 years of age and any race;&#xD;
&#xD;
          -  Have had a prior clinical SPECT MPI positive for ischemia in two myocardial segments&#xD;
             and referred for invasive coronary angiography (ICA) or have had a prior clinical&#xD;
             SPECT MPI negative for ischemia;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to receive and sign informed consent;&#xD;
&#xD;
          -  Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)&#xD;
             within 6-months prior to SPECT or in the intervening days between SPECT and PET&#xD;
             examination;&#xD;
&#xD;
          -  Participants who have received chemotherapeutic agents within 6 months of enrollment;&#xD;
&#xD;
          -  Heart failure (left ventricular ejection fraction â‰¤ 35%);&#xD;
&#xD;
          -  Known non-ischemic cardiomyopathy;&#xD;
&#xD;
          -  Inability to undergo pharmacologic stress testing with regadenoson (Lexiscan).&#xD;
             Contraindications include:&#xD;
&#xD;
               -  Symptomatic bradycardia or second to third degree atrioventricular (AV) block;&#xD;
&#xD;
               -  Pre-existing obstructive lung disease with active wheezing, i.e., COPD, asthma&#xD;
                  with active wheezing that precludes the safe administration of the&#xD;
                  pharmacological stress agent according to the approved label;&#xD;
&#xD;
               -  Uncontrolled and severe hypertension (e.g. systolic blood pressure &gt;200 mmHg,&#xD;
                  diastolic blood pressure &gt;110 mmHg);&#xD;
&#xD;
               -  Baseline hypotension (e.g. systolic blood pressure &lt; 90 mmHg, diastolic blood&#xD;
                  pressure &lt;50 mmHg);&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding;&#xD;
&#xD;
          -  Severe claustrophobia;&#xD;
&#xD;
          -  Weight â‰¥ 500 lbs (weight limit of PET/CT table)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela K Woodard, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dakkota M Thies</last_name>
    <phone>314-747-3839</phone>
    <email>d.thies@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kitty D Harrison, R.N</last_name>
    <phone>314-747-0183</phone>
    <email>kittydharrison@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dakkota m Thies</last_name>
      <phone>314-747-3839</phone>
      <email>d.thies@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kitty D Harrison, R.N</last_name>
      <phone>314-747-0183</phone>
      <email>kittydharrison@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pamela K Woodard, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schindler, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vijay Sharma, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sivapackiam J, Laforest R, Sharma V. 68Ga[Ga]-Galmydar: Biodistribution and radiation dosimetry studies in rodents. Nucl Med Biol. 2018 Apr;59:29-35. doi: 10.1016/j.nucmedbio.2017.11.008. Epub 2017 Dec 1.</citation>
    <PMID>29454148</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 13, 2022</study_first_submitted>
  <study_first_submitted_qc>November 20, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 20, 2022</last_update_submitted>
  <last_update_submitted_qc>November 20, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Pamela Woodard, MD</investigator_full_name>
    <investigator_title>H M Wilson Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>Myocardial Perfusion imaging</keyword>
  <keyword>Pharmacological Stress</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Myocardial Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

